Table 1.

Percentages of conformations capable of binding ATP and gefitinib

Variant EGFRATPGefitinib
WT17.2%16.7%
L858R9.5%15.5%

NOTE: Conformations were sampled from 2 × 10 μs molecular dynamics simulations for wild-type and L858R mutant EGFRs.